Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Pharma valuations: a skewed medicine - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Mar 28, 2000

    Pharma valuations: a skewed medicine

    Would you believe that the market capitalisation of Ranbaxy is more than the combined market capitalisation of Glaxo, Pfizer, SmithKline Pharma, Hoechst Marion Roussel, Burroughs Wellcome, E Merck, German Remedies, Knoll Pharma, Fulford and Abbott Laboratories put together?

    Ranbaxy is among the premier Indian pharmaceutical companies. It has an overall market share of 5.1%, owns 17 of the top 300 pharma brands and its width extends to almost 68% of the therapeutic area. It’s the market leader in antibiotic and antibacterial segments. Last year, Ranbaxy entered into a marketing arrangement for its new drug delivery system for ciprofloxacin with Bayer ABS. The company has ambitious plans to target the generic markets in the future. It is targeting one Novel Drug Delivery System every 18 months, filing ten Abbreviated New Drug Applications (ANDAs) every year and has two molecules under trials.

    However, there are problems. The domestic formulations market has grown by hardly 7% in FY2000 and the company has not been immune from the trend. While the company did succeed in maintaining operating margins for the full year, Ranbaxy’s fourth quarter was particularly disappointing with exports bailing out the company. (Exports contributed around 50% of the fourth quarter sales which grew overall by 3.6% vis-ŕ-vis the third quarter). Technology licensing income (from Bayer) accounted for 20% of the company’s pre-tax profit for the full year.

    The current year seems to be no different. Domestic formulation sales growth still seems to be in single digits. Usually, antibiotic sales are relatively lower post November and the current quarter is unlikely to be an exception. The Bayer deal is expected to bring in another $ 25 million in the current year. This works out to a pre–tax earnings of around Rs 10 per equity share, which is impressive no doubt.

    But one is not sure whether it justifies a market capitalisation that is more than the combined market capitalisation of Glaxo, Pfizer, SmithKline Pharma, Hoechst Marion Roussel, Burroughs Wellcome, E Merck, German Remedies, Knoll Pharma, Fulford and Abbott Laboratories put together.

    One reason for the stark difference in valuation between Ranbaxy and the multinational companies put together could be the concerns that investors have about these MNCs converting their existing operations into trading companies. The strategy that some of these seem to be following is (a) milk existing brands by transferring manufacturing to low-cost third parties and reduce overheads through VRS and the closure of own plants; (b) transfer profits where feasible through royalties and technical know how fees and (c) launch drugs through fully-owned subsidiaries. However, some large MNC's (e.g., Glaxo, Hoechst) are introducing more products and exploring possibilities of tie-ups and alliances to leverage their existing distribution strengths and franchise.

    (Rs m) Sales As % of
    Ranbaxy's sales
    PAT As % of
    Ranbaxy's profit
    ROE (Avg
    3 yrs)
    Three year
    compounded growth
    Ranbaxy 15,582   2,012   12.46% 10%
    Glaxo 8,855 57% 771 38% 19.5% 11%
    SmithKline 3,295 21% 247 12% 21.0% 17%
    Pfizer 3,645 23% 309 15% 22.0% 10%
    Hoechst 5,536 36% 200 10% 17.0% 3%
    Burroughs Wellcome 2,001 13% 293 15% 21.8% 3%
    E Merck 2,780 18% 181 9% 24.5% 11%
    German Remedies 2,080 13% 290 14% 29.2% 13%
    Knoll Pharma 2,910 19% 685 34% 40.9% 8%
    Fulford 1,060 7% (50)   - 3%
    Abbott 998 6% 45 2% 11.3% 13%
      33,160   2,972      

    In both cases, clearly, sentiment seems to have run ahead of fundamentals.



    Equitymaster requests your view! Post a comment on "Pharma valuations: a skewed medicine". Click here!


    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    The Power of 5 Minutes (The 5 Minute Wrapup)

    Jun 16, 2017

    Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 18, 2017 10:08 AM